DMT210 Topical Gel in the Treatment of Atopic Dermatitis

DMT210 Topical Gel in the Treatment of Mild to Moderate Atopic Dermatitis

The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).

Inclusion Criteria:

• Male or female 12 years or older
• Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement
• Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas
• Patient is willing and able to comply with the protocol

Exclusion Criteria:

• Patient has used topical therapies for AD within the Treatment Areas 2 weeks before baseline